CR20180499A - Inhibidores de mcl1 macrocicliclos para tratar el cancer - Google Patents
Inhibidores de mcl1 macrocicliclos para tratar el cancerInfo
- Publication number
- CR20180499A CR20180499A CR20180499A CR20180499A CR20180499A CR 20180499 A CR20180499 A CR 20180499A CR 20180499 A CR20180499 A CR 20180499A CR 20180499 A CR20180499 A CR 20180499A CR 20180499 A CR20180499 A CR 20180499A
- Authority
- CR
- Costa Rica
- Prior art keywords
- macrociclycles
- mcl1
- inhibitors
- treat cancer
- tridecaeno
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se da a conocer un compuesto que es ácido 17-cloro-5,13,14,22-tetrametil-28-oxa-2,9-ditia-5,6,12,13,22-pentaazaheptaciclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaeno-23-carboxílico (fórmula I)(I) y enantiómeros y sales farmacéuticamente aceptables del mismo. También se dan a conocer composiciones farmacéuticas de ácido 17-cloro-5,13,14,22-tetrametil-28-oxa-2,9-ditia-5,6,12,13,22-pentaazaheptacico [27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaeno-23-carboxílico, y enantiómeros y sales farmacéuticamente aceptables del mismo, y métodos de tratamiento del cáncer con tales compuestos y composiciones.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 | |
| PCT/EP2017/059511 WO2017182625A1 (en) | 2016-04-22 | 2017-04-21 | Macrocyclic mcl1 inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20180499A true CR20180499A (es) | 2019-01-25 |
Family
ID=58664658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20180499A CR20180499A (es) | 2016-04-22 | 2017-04-21 | Inhibidores de mcl1 macrocicliclos para tratar el cancer |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US9840518B2 (es) |
| EP (1) | EP3445767B1 (es) |
| JP (1) | JP6894449B2 (es) |
| KR (1) | KR102388208B1 (es) |
| CN (1) | CN109071566B (es) |
| AR (1) | AR108301A1 (es) |
| AU (1) | AU2017252222B2 (es) |
| BR (1) | BR112018070677B1 (es) |
| CA (1) | CA3020378A1 (es) |
| CL (1) | CL2018002410A1 (es) |
| CO (1) | CO2018008759A2 (es) |
| CR (1) | CR20180499A (es) |
| CY (1) | CY1123186T1 (es) |
| DK (1) | DK3445767T3 (es) |
| DO (1) | DOP2018000222A (es) |
| EA (1) | EA036551B1 (es) |
| ES (1) | ES2791319T3 (es) |
| HR (1) | HRP20200673T1 (es) |
| HU (1) | HUE049591T2 (es) |
| IL (1) | IL262237B (es) |
| LT (1) | LT3445767T (es) |
| MA (1) | MA44721B1 (es) |
| ME (1) | ME03729B (es) |
| MX (1) | MX2018012711A (es) |
| NI (1) | NI201800093A (es) |
| PE (1) | PE20181803A1 (es) |
| PH (1) | PH12018502227A1 (es) |
| PL (1) | PL3445767T3 (es) |
| PT (1) | PT3445767T (es) |
| RS (1) | RS60257B1 (es) |
| SG (1) | SG11201805838UA (es) |
| SI (1) | SI3445767T1 (es) |
| SV (1) | SV2018005742A (es) |
| TN (1) | TN2018000319A1 (es) |
| TW (1) | TWI742074B (es) |
| WO (1) | WO2017182625A1 (es) |
| ZA (1) | ZA201807766B (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108697729B (zh) | 2016-02-04 | 2023-05-09 | 约翰霍普金斯大学 | 新型GLUT抑制剂rapaglutin及其用途 |
| ES2837484T3 (es) | 2016-02-04 | 2021-06-30 | Univ Johns Hopkins | Rapadocinas, inhibidores del transportador de nucleósidos equilibrativo 1 y usos de los mismos |
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| CR20180499A (es) | 2016-04-22 | 2019-01-25 | Astrazeneca Ab | Inhibidores de mcl1 macrocicliclos para tratar el cancer |
| US10981932B2 (en) | 2016-05-19 | 2021-04-20 | Bayer Aktiengesellschaft | Macrocyclic indole derivatives |
| TWI781996B (zh) * | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| CN111818917A (zh) | 2017-08-15 | 2020-10-23 | 艾伯维公司 | 大环mcl-1抑制剂和使用方法 |
| US20200255451A1 (en) * | 2017-08-15 | 2020-08-13 | Abbvie Inc. | Macrocyclic mcl-1 inhibitors and methods of use |
| EP3710451A1 (en) * | 2017-11-17 | 2020-09-23 | Bayer Aktiengesellschaft | Substituted macrocyclic indole derivatives |
| WO2019096907A1 (en) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
| EP3710456B1 (en) | 2017-11-17 | 2022-09-21 | The Broad Institute, Inc. | Macrocyclic indole derivatives |
| WO2019096905A1 (en) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| EP3710450A1 (en) | 2017-11-17 | 2020-09-23 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| US11286263B2 (en) | 2017-11-17 | 2022-03-29 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| CA3113917A1 (en) * | 2018-09-30 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Indole macrocyclic derivative, preparation method therefor and application thereof in medicine |
| TW202344250A (zh) | 2018-11-14 | 2023-11-16 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN111205309B (zh) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| US11691989B2 (en) | 2018-11-22 | 2023-07-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic indoles as Mcl-1 inhibitors |
| WO2020151738A1 (en) * | 2019-01-23 | 2020-07-30 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrrazoles as mcl-1 inhibitors |
| SG11202109367WA (en) * | 2019-03-08 | 2021-09-29 | Zeno Management Inc | Macrocyclic compounds |
| TW202106693A (zh) * | 2019-04-30 | 2021-02-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚類大環衍生物、其製備方法及其在醫藥上的應用 |
| KR20220017931A (ko) | 2019-05-20 | 2022-02-14 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
| ES2975083T3 (es) * | 2019-06-21 | 2024-07-03 | Janssen Pharmaceutica Nv | Inhibidores macrocíclicos de MCL-1 |
| AU2020309745A1 (en) | 2019-07-09 | 2022-03-03 | Janssen Pharmaceutica Nv | Macrocyclic spirocycle derivatives as MCL-1 inhibitors |
| WO2021067405A1 (en) * | 2019-10-01 | 2021-04-08 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2021099580A1 (en) | 2019-11-21 | 2021-05-27 | Janssen Pharmaceutica Nv | Macrocyclic sulfonyl derivatives as mcl-1 inhibitors |
| CN114728985A (zh) | 2019-11-21 | 2022-07-08 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环吲哚衍生物 |
| CA3162963A1 (en) * | 2019-12-18 | 2021-06-24 | Zeno Management, Inc. | Macrocyclic compounds |
| US20230130109A1 (en) | 2020-02-21 | 2023-04-27 | Janssen Pharmaceutica Nv | Macrocyclic indole derivatives as inhibitors of mcl-1 |
| TW202144368A (zh) * | 2020-03-30 | 2021-12-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 吲哚類大環衍生物的結晶形式及其製備方法 |
| US20230265105A1 (en) * | 2020-05-29 | 2023-08-24 | Janssen Pharmaceutica Nv | Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1 |
| CN115943146A (zh) | 2020-06-19 | 2023-04-07 | 詹森药业有限公司 | N-连接的大环4-(吡唑-5-基)-吲哚衍生物作为mcl-1抑制剂 |
| WO2021255257A1 (en) | 2020-06-19 | 2021-12-23 | Janssen Pharmaceutica Nv | N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| AU2021306644A1 (en) | 2020-07-08 | 2023-03-09 | Janssen Pharmaceutica Nv | Macrocyclic ether containing indole derivatives as inhibitors of MLC-1 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| WO2022115451A1 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| KR20230121807A (ko) | 2020-12-17 | 2023-08-21 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 분지형 매크로사이클릭 4-(피라졸-5-일)-인돌유도체 |
| US20240190893A1 (en) | 2021-02-12 | 2024-06-13 | Janssen Pharmaceutica Nv | Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1 h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer |
| WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
| TW202317200A (zh) | 2021-06-11 | 2023-05-01 | 美商基利科學股份有限公司 | Ｍｃｌ－１抑制劑與抗體藥物接合物之組合 |
| TW202315637A (zh) | 2021-06-11 | 2023-04-16 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| CN115490708A (zh) * | 2021-06-18 | 2022-12-20 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| WO2023057484A1 (en) | 2021-10-06 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| TW202408588A (zh) | 2022-05-20 | 2024-03-01 | 瑞士商諾華公司 | 抗體-藥物結合物抗腫瘤化合物及其使用方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008242983B2 (en) * | 2007-04-16 | 2013-07-11 | Abbvie Inc. | 7-substituted indole Mcl-1 inhibitors |
| JP5496876B2 (ja) | 2007-04-16 | 2014-05-21 | アッヴィ・インコーポレイテッド | ７−置換されていないインドール系Ｍｃｌ−１阻害薬 |
| EP2674437A1 (en) * | 2008-12-22 | 2013-12-18 | Cubist Pharmaceuticals, Inc. | Novel antibacterial agents for the treatment of GRAM positive infections |
| EP2516416A1 (en) * | 2009-12-23 | 2012-10-31 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| KR101953210B1 (ko) * | 2011-05-19 | 2019-02-28 | 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ | 단백질 키나아제 억제제로서의 대환식 화합물 |
| US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
| WO2015031608A1 (en) | 2013-08-28 | 2015-03-05 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| EP3105236B1 (en) * | 2014-02-12 | 2017-10-18 | ViiV Healthcare UK (No.5) Limited | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| US10533010B2 (en) | 2014-03-27 | 2020-01-14 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| CU24399B1 (es) * | 2014-04-11 | 2019-04-04 | Bayer Pharma AG | Nuevos compuestos macrocíclicos en calidad de inhibidores de cdk9, un proceso para su preparación y los compuestos intermediarios útiles en la preparación de estos compuestos |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| CR20180499A (es) | 2016-04-22 | 2019-01-25 | Astrazeneca Ab | Inhibidores de mcl1 macrocicliclos para tratar el cancer |
-
2017
- 2017-04-21 CR CR20180499A patent/CR20180499A/es unknown
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/ko active IP Right Grant
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/es unknown
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/me unknown
- 2017-04-21 PT PT177207206T patent/PT3445767T/pt unknown
- 2017-04-21 SI SI201730246T patent/SI3445767T1/sl unknown
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/da active
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-04-21 ES ES17720720T patent/ES2791319T3/es active Active
- 2017-04-21 RS RS20200549A patent/RS60257B1/sr unknown
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/lt unknown
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/hu unknown
- 2017-04-21 MX MX2018012711A patent/MX2018012711A/es unknown
- 2017-04-21 MA MA44721A patent/MA44721B1/fr unknown
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/zh active Active
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/es unknown
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 AR ARP170101026A patent/AR108301A1/es unknown
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en active Application Filing
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 EA EA201892300A patent/EA036551B1/ru not_active IP Right Cessation
- 2017-04-21 PL PL17720720T patent/PL3445767T3/pl unknown
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/ja active Active
- 2017-04-21 CA CA3020378A patent/CA3020378A1/en active Pending
- 2017-04-21 TW TW106113380A patent/TWI742074B/zh active
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/pt active IP Right Grant
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/es unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/es unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/es unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/es unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-04-28 HR HRP20200673TT patent/HRP20200673T1/hr unknown
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/el unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20180499A (es) | Inhibidores de mcl1 macrocicliclos para tratar el cancer | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| CL2019002204A1 (es) | Compuestos inhibidores del vih. | |
| BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
| CO2019003482A2 (es) | Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética | |
| ECSP18094790A (es) | Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas | |
| NI201700056A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer | |
| ECSP16072941A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| CR20180516A (es) | Compuestos de iprrolotriazina como inhibidores de tam | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| PE20150887A1 (es) | Compuestos de benceno sustituidos | |
| UY36122A (es) | ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1? | |
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| NZ726608A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| NZ726360A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| CO2021005532A2 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| BR112018008506B8 (pt) | Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos | |
| CR20160600A (es) | Quinolizione derivados como inhibidores pi3k | |
| BR112016020556A8 (pt) | compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto | |
| AR105400A1 (es) | Inhibidores de jak1 | |
| SV2016005317A (es) | Derivados de pirrolidina -2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1 | |
| BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
| CR20160532A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1 |